[204 Pages Report] The global preimplantation genetic testing market is projected to reach to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.

Objectives of the study are:

To define, describe, and forecast the global preimplantation genetic testing market by technology, product & service, procedure type, application, end user, and region

To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges)

To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the total market

To analyze the growth opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

To forecast the market value of the market segments with respect to four major regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW)

To profile the key players and comprehensively analyze their market shares and core competencies

To track and analyze competitive developments such as product launches, showcases, and approvals; partnerships, agreements, and collaborations; acquisitions; and expansions in the global preimplantation genetic testing market

Research Methodology

This research study involved the extensive use of secondary sources, directories, and databases (such as Hoovers, Bloomberg Business, Factiva, and Avention) to identify and collect information useful for this technology-based, market-oriented, and commercial study of the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents that mainly included key industry participants, subject-matter experts (SMEs), C & D level executives of key market players, and independent industry consultants, among others; to obtain and verify critical qualitative and quantitative information as well as to assess future market prospects of the global preimplantation genetic testing industry.

The secondary sources referred to for this research study include corporate filings (such as annual reports, SEC filings, investor presentations, and financial statements); research journals; press releases; as well as articles published by various trade, business, and professional associations

To know about the assumptions considered for the study, download the pdf brochure

Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), and Beijing Genomics Institute (BGI) (China) are some of the key players in the global preimplantation genetic testing market. These players are striving to expand their presence in the emerging countries of Asia-Pacific and the Middle East & North Africa (MENA) regions through product launches, partnerships, agreements, and collaborations.

Stakeholders

Preimplantation Genetic Diagnosis and Screening Product Manufacturing Companies

Preimplantation Genetic Diagnosis and Screening Service Providers

Suppliers/Distributors

Fertility Clinics and Maternity Centers

Clinical Research Organizations (CROs)

Academic Institutes and Research Institutes

Medical Reimbursement and Insurance Providers

Independent and Government Regulatory Bodies

Scope of the Report

This research report categorizes the preimplantation genetic testing market into the following segments and subsegments:

Preimplantation Genetic Testing Market: By Technology

Next Generation Sequencing (NGS)

Polymerase Chain Reaction (PCR)

Fluorescent In-Situ Hybridization (FISH)

Comparative Genomic Hybridization (CGH)

Single Nucleotide Polymorphism (SNP)

Preimplantation Genetic Testing Market: By Product & Service

Reagents & Consumables

Instruments

Software & Services

Preimplantation Genetic Testing Market: By Procedure Type

Preimplantation Genetic Screening

Preimplantation Genetic Diagnosis

Preimplantation Genetic Testing Market: By Application

Aneuploidy

Structural Chromosomal Abnormalities Translocations Deletions Duplications Inversions

Single Gene Disorders

X-linked Disorders

HLA Typing

Gender Identification

Preimplantation Genetic Testing Market: By End User

Maternity Centers & Fertility Clinics

Hospitals, Diagnostic Labs, and Service Providers

Research Laboratories & Academic Institutes

Preimplantation Genetic Testing Market: By Region

North America U.S. Canada

Europe Germany U.K. France Rest of Europe (RoW)

Asia-Pacific China Japan India Rest of Asia-Pacific (RoAPAC)

Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company�s specific needs. The following customization options are available for the report:

Product Analysis

Product matrix which gives a detailed comparison of the product portfolios of the top five companies

Geographical Analysis

Country-wise breakdown of preimplantation genetic testing market in Rest of Europe (RoE), Rest of Asia-Pacific (RoAPAC), and the Rest of the World (RoW)

Company Information

Detailed analysis and profiling of additional market players (up to 5)

The global preimplantation genetic testing market is expected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%. The growth of this market is majorly driven by the rising rate of infertility across the globe, increasing number of fertility clinics worldwide, public-private investments in the field of preimplantation genetic testing, technological advancements in the field of genetic analysis, and the high risk of chromosomal abnormalities in the fetus with increasing maternal age.

The report analyzes the global preimplantation genetic testing market by technology, product & service, procedure type, application, end user, and region. Based on technology, the next-generation sequencing (NGS) segment accounted for the largest share owing to the advantages offered by NGS such as reduced cost, better ability to detect an embryo with differing results (mosaicism), enhanced detection of structural abnormalities such as chromosomes, and reduction in human errors due to increased automation.

By product & service, the reagents & consumables segment accounted for the largest market share owing to expanding application horizons of specific technologies (such as NGS and aCGH for whole-genome sequencing and FISH in the diagnosis of specific genetic disorders). Based on procedure type, the genetic screening segment accounted for the largest share due to continuous decline in female fertility (due to rising maternal age) and benefits offered by PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.

In terms of application, the aneuploidy segment held the largest share in 2016. Factors such as increasing maternal age and rising incidence of aneuploidy have led to the growth of this segment. Among end users, the maternity centers & fertility clinics segment accounted for the largest share of the global preimplantation genetic testing market due to factors such as increasing number of fertility centers and the high treatment success rate at such centers.

This report covers the preimplantation genetic testing market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America accounted for the largest share of the global preimplantation genetic testing market in 2016, followed by Europe. The large share in the North American region is mainly attributed to the rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, and the ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS). The Asia-Pacific region is expected to register the highest growth rate during the forecast period, due to the growing focus of players on emerging markets and improvements in healthcare infrastructure in these regions.

The high procedural cost associated with preimplantation genetic testing and unsupportive government regulations are the key factors restraining the growth of this market.

Illumina, Inc. (U.S.) dominates the market through its wide range of technologically advanced and innovative preimplantation genetic testing products. The company adopts the strategy of agreements and partnerships to maintain its leadership position in the market.

Other prominent players in the preimplantation genetic testing market are Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Genea Limited (Australia), Rubicon Genomics, Inc. (U.S.), and Oxford Gene Technology (U.K.), among others.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst